Sodium-glucose cotransporter 2 (SGLT2) inhibitors induce ketosis in patients with diabetes mellitus type 2 (5.6 ± 6.0 μmol/L when fasting and 3.3 ± 3.8 μmol/L when fed), but not in patients without diabetes (35) and reduce the risk of cardiovascular death and hospitalization for heart failure in both groups (36, 37). This evidence concerns the gene SLC5A2 and heart failure.